Pulmatrix Inc PULM Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.36 down $0.05, 3.55% at close Oct 16
Last close · Previous close $1.41
- Market cap
- At the Oct 16 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.10Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$1.36down $0.05, 3.55%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.41Oct 15
- Volume14.97KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume33.01KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.16 to $5.24; now $1.36
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
PULM trailed the S&P 500 in all 7 periods.
| Period | PULM and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PULM: down 2.9% S&P 500: up 1.5% | PULM trailed the S&P 500 by 4.4 percentage points Trailed |
| 3M | PULM: down 15.5% S&P 500: up 1.9% | PULM trailed the S&P 500 by 17.4 percentage points Trailed |
| YTD | PULM: down 39.0% S&P 500: up 12.8% | PULM trailed the S&P 500 by 51.8 percentage points Trailed |
| 1Y | PULM: down 70.7% S&P 500: up 16.8% | PULM trailed the S&P 500 by 87.5 percentage points Trailed |
| Long term | ||
| 3Y | PULM: down 32.3% S&P 500: up 81.5% −12.2% vs +22.0% a year | PULM trailed the S&P 500 by 113.8 percentage points Trailed |
| 5Y | PULM: down 90.6% S&P 500: up 83.1% −37.7% vs +12.9% a year | PULM trailed the S&P 500 by 173.7 percentage points Trailed |
| 10Y | PULM: down 99.5% S&P 500: up 319.6% −41.2% vs +15.4% a year | PULM trailed the S&P 500 by 419.1 percentage points Trailed |
$10,000 invested in PULM 10 years ago (Oct 14, 2016) would be worth about $49 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
PULM trailed the S&P 500 in all 7 periods.
| Period | PULM and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PULM: down 2.9% S&P 500: up 1.2% | PULM trailed the S&P 500 by 4.1 percentage points Trailed |
| 3M | PULM: down 15.5% S&P 500: up 1.7% | PULM trailed the S&P 500 by 17.2 percentage points Trailed |
| YTD | PULM: down 39.0% S&P 500: up 11.9% | PULM trailed the S&P 500 by 50.9 percentage points Trailed |
| 1Y | PULM: down 70.7% S&P 500: up 15.5% | PULM trailed the S&P 500 by 86.2 percentage points Trailed |
| Long term | ||
| 3Y | PULM: down 32.3% S&P 500: up 75.0% −12.2% vs +20.5% a year | PULM trailed the S&P 500 by 107.3 percentage points Trailed |
| 5Y | PULM: down 90.6% S&P 500: up 71.2% −37.7% vs +11.4% a year | PULM trailed the S&P 500 by 161.8 percentage points Trailed |
| 10Y | PULM: down 99.5% S&P 500: up 258.1% −41.2% vs +13.6% a year | PULM trailed the S&P 500 by 357.6 percentage points Trailed |
$10,000 invested in PULM 10 years ago (Oct 14, 2016) would be worth about $49 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$3,625.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Mar 21, 2014.
Stock splits
3
Latest: 1-for-20 on . Share counts adjust after each split.
All 3 splits
- 1-for-20
- 1-for-10
- 2-for-5
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00down 100.0%
- Net income
- −$4.01M
- Diluted EPS
- −$1.10
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $366.00K | −$2.59M | −$0.71 |
| Q4 FY24 (Dec 31, 2024) | $3.00K | −$1.99M | −$0.55 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$1.81M | −$0.50 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$1.55M | −$0.42 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$877.00K | −$0.24 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$928.00K | −$0.25 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$1.17M | −$0.32 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$1.04M | −$0.29 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $5.17M | −$20.17M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $6.07M | −$18.84M | −$5.46 |
| FY23 (Dec 31, 2023) | $7.30M | −$14.12M | −$3.87 |
| FY24 (Dec 31, 2024) | $7.81M | −$9.56M | −$2.62 |
| FY25 (Dec 31, 2025) | $0.00 | −$5.16M | −$1.41 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$3.91MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$3.91MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $0.00Last 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $2.88MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$2.88MAs of Jun 30, 2026
- 4.70As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −109.3%Last 12 months
Over the last 12 months, Pulmatrix lost money: its net loss was 109.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −95.2%Last 12 months
Over the last 12 months, Pulmatrix’s net loss was 95.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Pulmatrix Inc
Pulmatrix is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. For more on the Company's inhaled product candidates please visit: https://www.pulmatrix.com/pipeline.html. About Eos SENOLYTIX, Inc. Eos SENOLYTIX is a biotechnology company focused on developing first-in-class gerotherapeutic peptide medicines that target the underlying biological mechanisms of aging. Eos's lead clinical candidates, PTC-2105 and PTC-2107, both proprietary MitoXcel™ geropeptides, have demonstrated the ability to rejuvenate naturally aged mice via two separate mechanisms, both via a single, aging-specific target, the mitochondrial membrane potential (MMP), also called the "Δψm". These two mechanisms include (1) the return of the efficiency of mitochondrial. Merger-associated financings are expected to support advancement of the combined company's pipeline through key clinical milestones. Eos is led by Kevin Slawin, M.D., Founder and Chief Executive Officer, a physician-scientist and serial biotechnology entrepreneur with decades of experience in translational medicine, drug development, and company formation. Dr. Slawin was the founder of Bellicum Pharmaceuticals, Inc., an early pioneer in CAR T cell therapies, and has founded and is currently leading multiple life sciences ventures focused on aging biology and mitochondrial therapeutics. He is supported by a team of experienced biotechnology executives, scientists, and advisors with prior leadership roles at major pharmaceutical companies, academic medical centers, and emerging biotechnology firms.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
PULM news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
PULM stock FAQ
What is PULM stock’s price today?
Pulmatrix (PULM) traded at $1.36 at the close on , down $0.05 (3.55%) from the previous close of $1.41. Over the past 52 weeks it has traded between $1.16 and $5.24.
If you invested $1,000 in PULM 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in PULM on would be worth about $5 at the close on , a total return of −99.5%. The same $1,000 would be worth $94 if invested five years ago and $293 if invested one year ago. Past performance doesn’t predict future returns.
What is PULM’s P/E ratio?
PULM’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.10).
What are PULM’s earnings per share?
PULM’s diluted earnings per share were −$1.10 over the four quarters to , compared with −$2.18 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.29 per share, against −$0.42 a year earlier (how EPS works).
Does PULM pay a dividend?
Pulmatrix hasn’t paid a dividend in the last twelve months.
What is PULM’s 52-week high and low?
Over the past 52 weeks PULM has traded as low as $1.16 and as high as $5.24. At $1.36 at the close on , it is 74.0% below that high and 17.2% above the low.
What is PULM’s all-time high?
PULM’s highest closing price was $3,625.00 on , adjusted for stock splits. At $1.36 at the close on , it is 100.0% below that record.
Has PULM stock ever split?
Yes, three times: 2-for-5 on ; 1-for-10 on ; 1-for-20 on .
How has PULM stock performed?
Including dividends and measured to the close on , PULM has returned −39.0% so far this year and −70.7% over the past year, and −90.6% over five years (−37.7% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Pulmatrix in?
Pulmatrix is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does PULM trade on?
Pulmatrix trades on the Nasdaq under the ticker symbol PULM. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.